[1]周俊,罗素珊,潘海燕.血清抗磷脂酶A2受体抗体表达与特发膜性肾病相关性[J].青岛大学学报(医学版),2018,54(04):439-442.[doi:10.11712/jms201804015]
 ZHOU Jun,LUO Sushan,PAN Haiyan.ASSOCIATION OF THE EXPRESSION OF ANTI-PHOSPHOLIPASE A2 RECEPTOR ANTIBODY IN SERUM WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY[J].JOURNAL OF QINGDAO UNIVERSITY (MEDICAL SCIENCES),2018,54(04):439-442.[doi:10.11712/jms201804015]
点击复制

血清抗磷脂酶A2受体抗体表达与特发膜性肾病相关性()
分享到:

《青岛大学学报(医学版)》[ISSN:2096-5532/CN:37-1217/R]

卷:
第54卷
期数:
2018年04期
页码:
439-442
栏目:
出版日期:
2018-07-05

文章信息/Info

Title:
ASSOCIATION OF THE EXPRESSION OF ANTI-PHOSPHOLIPASE A2 RECEPTOR ANTIBODY IN SERUM WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY
文章编号:
2096-5532(2018)04-0439-04
作者:
周俊罗素珊潘海燕
(惠州市第三人民医院肾内科,广东 惠州〓516000)
Author(s):
ZHOU Jun LUO Sushan PAN Haiyan
(Department of Nephrology, the Third People’s Hospital of Huizhou, Huizhou 516000, China)
关键词:
抗磷脂酶A2受体肾小球肾炎 膜性治疗结果
Keywords:
anti phospholipase A2 receptor glomerulonephritis membranous treatment outcome
分类号:
R692.31
DOI:
10.11712/jms201804015
文献标志码:
A
摘要:
目的 探讨血清抗磷脂酶A2受体(PLA2R)抗体表达与特发膜性肾病(IMN)的相关性,以及治疗后其水平下降与膜性肾病临床缓解的相关性。
方法 选取IMN病人100例,采用糖皮质激素联合环磷酰胺方案治疗6个月。每月治疗前复查抗PLA2R抗体、24 h尿蛋白定量、血清清蛋白,并评定疗效。
结果 血清抗PLA2R抗体阳性65例(阳性组),阴性35例(阴性组);阳性组病人24 h尿蛋白定量明显高于阴性组(t=4.045,P<0.05),血浆清蛋白明显低于阴性组(t=-5.112,P<0.05);阴性组治疗后临床缓解率为97.14%,明显高于阳性组(Z=3.882,P<0.05);阴性组达到临床缓解的中位时间为8.45个月,明显短于阳性组(χ2=24.046,P<0.05)。血清抗PLA2R抗体阳性组病人根据抗体滴度分为低滴度组(n=21)和高滴度组(n=44),低滴度组疗效明显高于高滴度组(Z=3.457,P<0.05);低滴度组达到临床缓解的中位时间为12.18个月,明显短于高滴度组(χ2=17.684,P<0.05)。
结论 血清抗PLA2R抗体表达与IMN有一定联系,在预测病人治疗效果方面可能有一定作用。
Abstract:
Objective To investigate the association of the expression of anti-phospholipase A2 receptor (anti-PLA2R) antibody in serum with idiopathic membranous nephropathy (IMN), as well as the association of the reduction in anti-PLA2R antibody after treatment with clinical remission of membranous nephropathy.
Methods A total of 100 patients with IMN were enrolled and were treated with glucocorticoid and cyclophosphamide for 6 months. Anti-PLA2R antibody, 24 h urine protein, and serum albumin were measured before treatment every month.
Results Of all patients, 65 had positive serum anti-PLA2R antibody (positive group) and 35 had negative serum anti-PLA2R antibody (negative group). Compared with the negative group, the positive group had significantly higher 24 h urine protein excretion (t=4.045,P<0.05) and a significantly lower level of plasma albumin (t=-5.112,P<0.05). After treatment, the negative group had a clinical remission rate of 97.14%, which was significantly higher than that in the positive group (Z=3.882,P<0.05); the median time to clinical remission in the negative group was 8.45 months, which was significantly shorter than that in the positive group (χ2=24.046,P<0.05). According to antibody titer, the patients in the positive group were further divided into low titer group with 21 patients and high titer group with 44 patients. The low titer group had a significant better clinical outcome than the high titer group (Z=3.457,P<0.05). The median time to clinical remission in the low titer group was 12.18 months, which was significantly shorter than that in the high titer group (χ2=17.684,P<0.05).
Conclusion The expression of anti-PLA2R antibody in serum is associated with IMN and may play a role in predicting the treatment outcome of patients.
更新日期/Last Update: 2018-07-08